CARsgen Seizes China Precision Medicine Opportunity, Looks Globally
This article was originally published in PharmAsia News
Executive Summary
Amid China’s big push into precision medicine, the Chinese bioventure CARsgen is developing what it says is the world’s first CAR-T cell immunotherapy for liver cancer and is seeking a global partner to develop its proprietary therapies. The company is also aiming to raise additional funding to advance its pipeline.